Last €1.94 EUR
Change Today +0.139 / 7.71%
Volume 0.0
BT3 On Other Exchanges
Symbol
Exchange
BT3 is not on other exchanges.
As of 2:08 AM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

biotime inc (BT3) Snapshot

Open
€1.93
Previous Close
€1.80
Day High
€1.94
Day Low
€1.93
52 Week High
06/4/13 - €3.62
52 Week Low
04/15/14 - €1.80
Market Cap
135.2M
Average Volume 10 Days
2.1K
EPS TTM
--
Shares Outstanding
69.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIME INC (BT3)

biotime inc (BT3) Related Businessweek News

No Related Businessweek News Found

biotime inc (BT3) Details

BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReGlyde, a cross-linked thiol-modified hyaluronan hydrogel to manage and protect tendon injuries; and Premvia, a hydrogel formulation to manage wounds, as well as PanC-Dx, a non-invasive cancer products for use in detecting breast, bladder, and lung cancers. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. Additionally, the company develops cell based therapeutic products for diseases, such as neurological disorders, age related macular degeneration, orthopedic disorders, and cardiovascular disease and related ischemic disorders. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

106 Employees
Last Reported Date: 03/17/14
Founded in 1990

biotime inc (BT3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $760.5K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $431.9K
Chief Commercial Officer
Total Annual Compensation: $257.5K
Compensation as of Fiscal Year 2012.

biotime inc (BT3) Key Developments

BioTime, Inc. Announces Board Changes

On April 7, 2014, Henry L. Nordhoff and Andrew C. von Eschenbach resigned from BioTime, Inc.'s Board of Directors. Mr. Nordhoff had served on Audit Committee. Dr. von Eschenbach had served on Nominating/Corporate Governance Committee and the company's Science and Technology Committee. Mr. Nordhoff and Dr. von Eschenbach informed that they were resigning from the BioTime Board of Directors in order to focus their attention on the therapeutic stem cell business of the company's subsidiary Asterias Biotherapeutics, Inc. Mr. Nordhoff also informed that his decision to resign from Board was influenced by an offer he had received to serve as the executive chairman of a new company that might compete with another BioTime subsidiary. On April 9, 2014, Board of Directors appointed Deborah Andrews and David Schlachet to the Board of Directors, effective on April 11, 2014, to fill the vacancies created by the resignations of Mr. Nordhoff and Dr. von Eschenbach. Mr. Schlachet served as chairman of Syneron Medical Ltd. from April 2013 to February 2014. Deborah Andrews served as Vice President-Chief Accounting Officer of STAAR Surgical Company since 2013, and served as STAAR Surgical's Vice President-Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President-International Finance from 1999 to 2001.

BioTime, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 01:40 PM

BioTime, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 01:40 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Michael D. West, Chief Executive Officer, President and Director.

BioTime, Inc. Announces Board Changes

On March 21, 2014, BioTime, Inc. announced that Franklin M. Berger was resigning from board of directors. Mr. Berger had served on Audit Committee and Compensation Committee. Board of Directors has appointed Pedro Lichtinger to serve on the Audit Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BT3:GR €1.94 EUR +0.139

BT3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Cell Technology Inc $0.06 USD -0.0019
Athersys Inc $2.64 USD -0.06
Cytori Therapeutics Inc $2.25 USD -0.03
Geron Corp $1.86 USD -0.03
NeoStem Inc $6.43 USD -0.36
View Industry Companies
 

Industry Analysis

BT3

Industry Average

Valuation BT3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.0x
Price/Book 10.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIME INC, please visit www.biotimeinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.